Cue Biopharma, Inc. CUE shares are trading lower on Tuesday. The company reported 2024 fiscal-year earnings on Monday after ...

With the CSF-1R inhibitor space heating up, Germany's Merck Group has gone all-in on pimicotinib, paying Abbisko Therapeutics ...

Research and development expenses were $36.3 million and $40.8 million for the years ended December 31, 2024 and 2023, respectively. The decrease was primarily due to decreases in clinical trial costs ...